Amarin Shuffles Management Again, But Says Omega-3 Trial Results Are Near
This article was originally published in The Pink Sheet Daily
Executive Summary
On a quarterly earnings call, Amarin's new CEO says two Phase III trials of a drug to lower triglycerides will yield results a few months ahead of schedule.
You may also be interested in...
Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch
With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.
Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch
With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.
Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa
Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.